These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 17854237)

  • 1. Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
    Tam SW; Sabolinski ML; Worcel M; Packer M; Cohn JN
    Clin Pharmacokinet; 2007; 46(10):885-95. PubMed ID: 17854237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination.
    Cheng JW
    Clin Ther; 2006 May; 28(5):666-78. PubMed ID: 16861089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study of the bioequivalence of a new isosorbide dinitrate tablet formulation compared with the standard preparation].
    Metzner JE; Buchberger D; Häring N; Läuter J
    Arzneimittelforschung; 1997 Jun; 47(6):719-26. PubMed ID: 9281301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fixed-Dose Versus Off-Label Combination of Isosorbide Dinitrate Plus Hydralazine Hydrochloride: Retrospective Propensity-Matched Analysis in Black Medicare Patients with Heart Failure.
    Ofili E; Anand I; Williams RA; Akinboboye O; Xu L; Puckrein G
    Adv Ther; 2017 Aug; 34(8):1976-1988. PubMed ID: 28707284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations].
    Scheidel B; Blume H; Stenzhorn G; Siewert M; Babej-Dölle RM
    Arzneimittelforschung; 1991 Mar; 41(3):212-8. PubMed ID: 1867657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
    Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations.
    Vree TB; Dammers E; Valducci R
    Int J Clin Pharmacol Ther; 2004 Aug; 42(8):463-72. PubMed ID: 15366327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isosorbide dinitrate/hydralazine: its role in the treatment of heart failure.
    Thadani U; Jacob RG
    Drugs Today (Barc); 2008 Dec; 44(12):925-37. PubMed ID: 19198701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of nitrates and hydralazine in heart failure: clinical evidence before the african american heart failure trial.
    Elkayam U; Bitar F
    Am J Cardiol; 2005 Oct; 96(7B):37i-43i. PubMed ID: 16226934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BiDil (isosorbide dinitrate and hydralazine): a new fixed-dose combination of two older medications for the treatment of heart failure in black patients.
    Carmody MS; Anderson JR
    Cardiol Rev; 2007; 15(1):46-53. PubMed ID: 17172884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative bioavailability of two isosorbide dinitrate sublingual tablet formulations administered as single doses in healthy subjects.
    Niopas I; Daftsios AC; Nikolaidis N
    Int J Clin Pharmacol Ther; 2001 May; 39(5):224-8. PubMed ID: 11380069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacokinetics of isosorbide nitrates after repeated doses of sustained release isosorbide dinitrate.
    Laufen H; Leitold M; Wildfeuer A
    Arzneimittelforschung; 1988 Sep; 38(9):1336-41. PubMed ID: 3223973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Ziesche S; Cobb FR; Cohn JN; Johnson G; Tristani F
    Circulation; 1993 Jun; 87(6 Suppl):VI56-64. PubMed ID: 8500241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure.
    Angus DC; Linde-Zwirble WT; Tam SW; Ghali JK; Sabolinski ML; Villagra VG; Winkelmayer WC; Worcel M;
    Circulation; 2005 Dec; 112(24):3745-53. PubMed ID: 16344404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the bioequivalence and pharmacokinetics of two tablet formulations of isosorbide-5-mononitrate after single oral administration in healthy volunteers.
    Niopas I; Daftsios AC; Nikolaidis N
    Arzneimittelforschung; 2002; 52(3):182-6. PubMed ID: 11963645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study.
    Li KY; Liang JP; Hu BQ; Qiu Y; Luo CH; Jiang Y; Lin XP; Yang N
    Clin Ther; 2010 Aug; 32(9):1674-80. PubMed ID: 20974325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed combination isosorbide dinitrate-hydralazine for nitric-oxide-enhancing therapy in heart failure.
    Franciosa JA
    Expert Opin Pharmacother; 2006 Dec; 7(18):2521-31. PubMed ID: 17150006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Francis GS; Cohn JN; Johnson G; Rector TS; Goldman S; Simon A
    Circulation; 1993 Jun; 87(6 Suppl):VI40-8. PubMed ID: 8500238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group.
    Loeb HS; Johnson G; Henrick A; Smith R; Wilson J; Cremo R; Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI78-87. PubMed ID: 8500244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.